Non-Small Cell Lung Cancer - Oncology Matrix

Efficacy and Safety of Olomorasib in Combination With Pembrolizumab in Treatment of Patients With KRAS G12C-Mutant Advanced NSCLC

Research Summary: KRAS G12C mutations occur in a substantial subset of advanced non-small cell lung cancer (NSCLC), and current first-line standards based on immune checkpoint inhibitors (ICIs), with or without chemotherapy, yield suboptimal long-term outcomes. Olomorasib is an orally bioavailable, highly selective KRAS G12C inhibitor...

Prognostic Impact of KRAS and SMARCA4 Mutations and Comutations on Survival in Non-Small Cell Lung Cancer: Insights from the AACR GENIE BPC Dataset

Reprinted with permission. Biomedicines. 2025;13(9):2142.* by Peter Manolakos, Yu-Bo Wang, Janice Withycombe, Luigi Boccuto, and Diana Ivankovic Dr. Manolakos is with Healthcare Genetics and Genomics PhD Program, Clemson University in Clemson, South Carolina. Dr. Bo-Wang is with School of Mathematical and Statistical Sciences, Clemson University...

European Society for Medical Oncology Congress 2025: Non-Small Cell Lung Cancer

Molecular characteristics and overall survival of STK11-mutant NSCLC according to KRAS mutation status. In this study, researchers compared clinical and molecular differences between STK11-mutant/KRAS-mutant non-small cell lung cancer (NSCLC) and STK11-mutant/KRAS-wildtype NSCLC. Data from 2022 to 2024 were included for analysis. Among 808 patients with...

Durvalumab Alone or Combined With Novel Agents for Unresectable Stage III Non-small Cell Lung Cancer: Update From the COAST Randomized Clinical Trial

Research Summary: Durvalumab after concurrent chemoradiotherapy (cCRT) is standard-of-care for patients with unresectable, Stage III non-small cell lung cancer (NSCLC) without progression. The COAST study evaluated whether adding novel immunotherapies targeting cluster of differentiation 73 (CD73; oleclumab) or natural killer Group 2 member A (NKG2A;...

ESMO Congress 2025 Meeting Highlights: Non-Small Cell Lung Cancer

Osimertinib then chemotherapy in EGFR-mutated lung cancer with osimertinib third-line rechallenge (OCELOT-cohort A interim analysis). This ongoing multicenter Phase II trial is evaluating third-line (3L) osimertinib rechallenge in patients with epidermal growth factor receptor mutation–positive (EGFR+) advanced non-small cell lung cancer (NSCLC) after first-line osimertinib...

Journal Watch: Hot Topics in Non-small Cell Lung Cancer December 2025

Real-world outcomes and subsequent treatment patterns in patients with advanced non-small cell lung cancer and atypical EGFR mutations receiving first-line osimertinib monotherapy Nieva JJ, Wang X, Doroshow D, et al. Oncol Ther. 2025. Epub ahead of print. Summary. Researchers assessed outcomes of first-line osimertinib monotherapy...

Neoadjuvant Osimertinib for Resectable EGFR-mutated Non-small Cell Lung Cancer

Research Summary In this randomized, controlled, Phase III study,1 patients with resectable, epidermal growth factor receptor (EGFR)–mutated, Stage II to IIIB non-small cell lung cancer (NSCLC) were assigned 1:1:1 to receive neoadjuvant osimertinib (80mg orally once daily for at least nine weeks) plus platinum-based chemotherapy...

Digital Editions